BioCentury
ARTICLE | Clinical News

Orkambi ivacaftor/lumacaftor: Phase III data

February 1, 2016 8:00 AM UTC

An open-label, U.S. Phase III trial in 58 CF patients ages 6-11 with 2 copies of the delta F508 CFTR mutation showed that twice-daily Orkambi for 24 weeks met the primary safety endpoint. Orkambi was ...